| NCT07029581 | Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis | RECRUITING | PHASE2 | 2025-08-06 | 2028-03 | 2028-02 |
| NCT07095465 | Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis | NOT_YET_RECRUITING | PHASE3 | 2025-08 | 2029-03 | 2029-02 |
| NCT06194799 | ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study | ENROLLING_BY_INVITATION | PHASE3 | 2024-04-23 | 2029-05 | 2029-04 |
| NCT06420297 | OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome | ENROLLING_BY_INVITATION | PHASE3 | 2024-03-11 | 2029-06 | 2029-05 |
| NCT06173531 | Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-11-27 | 2025-11 | 2025-10 |
| NCT06159673 | ACP-204 in Adults With Alzheimer's Disease Psychosis | RECRUITING | PHASE2, PHASE3 | 2023-11-14 | 2028-02 | 2028-01 |
| NCT05555615 | Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder | TERMINATED | PHASE2, PHASE3 | 2022-11-02 | 2025-02-14 | 2025-02-14 |
| NCT05523895 | Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder | COMPLETED | PHASE2, PHASE3 | 2022-08-09 | 2024-09-27 | 2024-09-27 |
| NCT04988867 | An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome | TERMINATED | PHASE2, PHASE3 | 2021-09-22 | 2023-05-31 | 2023-05-31 |
| NCT05008835 | Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee | TERMINATED | PHASE2 | 2021-07-20 | 2022-11-16 | 2022-10-06 |
| NCT04855240 | Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy | COMPLETED | PHASE2 | 2021-03-29 | 2022-03-14 | 2022-02-11 |
| NCT04776746 | Open-Label Extension Study of Trofinetide for Rett Syndrome | TERMINATED | PHASE3 | 2020-11-08 | 2023-06-30 | 2023-06-30 |
| NCT04531982 | Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia | COMPLETED | PHASE3 | 2020-08-05 | 2024-02-19 | 2024-01-25 |
| NCT04292223 | Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis | COMPLETED | PHASE4 | 2020-02-10 | 2022-04-26 | 2022-04-26 |
| NCT04279314 | Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome | COMPLETED | PHASE3 | 2020-01-29 | 2022-08-19 | 2022-08-19 |
| NCT04181723 | Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDERâ„¢) | COMPLETED | PHASE3 | 2019-11-06 | 2021-10-28 | 2021-10-28 |
| NCT04164758 | Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine | TERMINATED | PHASE2 | 2019-10-23 | 2020-09-25 | 2020-09-25 |
| NCT04000009 | Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment | TERMINATED | PHASE3 | 2019-06-06 | 2021-02-22 | 2021-02-22 |
| NCT03968159 | Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment | COMPLETED | PHASE3 | 2019-04-25 | 2020-05-29 | 2020-04-30 |
| NCT03623321 | Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease | COMPLETED | PHASE3 | 2018-07-17 | 2023-05-05 | 2023-05-05 |
| NCT03575052 | A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease | COMPLETED | PHASE3 | 2018-05-21 | 2022-05-06 | 2022-05-06 |
| NCT03482882 | Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression | COMPLETED | PHASE2 | 2018-03-09 | 2019-07-24 | 2019-07-09 |
| NCT03325556 | Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis | COMPLETED | PHASE3 | 2017-09-27 | 2019-10-30 | 2019-07-31 |
| NCT03118947 | A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease | COMPLETED | PHASE2 | 2017-02-23 | 2019-02-25 | 2019-02-25 |
| NCT03121586 | Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia | TERMINATED | PHASE3 | 2017-01 | 2024-05-30 | 2024-04-30 |
| NCT03018340 | Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY) | COMPLETED | PHASE2 | 2016-12 | 2018-10 | 2018-09 |
| NCT02970305 | Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE) | COMPLETED | PHASE2 | 2016-11-04 | 2019-10-28 | 2019-10-16 |
| NCT02992132 | Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE) | TERMINATED | PHASE2 | 2016-11 | 2018-02-16 | 2018-01-25 |
| NCT02970292 | Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1) | COMPLETED | PHASE3 | 2016-10-26 | 2019-06-25 | 2019-05-28 |
| NCT02035553 | A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis | COMPLETED | PHASE2 | 2013-11 | 2016-10-27 | 2016-09-28 |
| NCT01174004 | A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis | COMPLETED | PHASE3 | 2010-07 | 2012-11 | 2012-11 |
| NCT00658567 | A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | COMPLETED | PHASE3 | 2008-03 | 2009-12 | 2009-12 |
| NCT00550238 | A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | COMPLETED | PHASE3 | 2007-07 | 2018-05-30 | 2018-05-30 |
| NCT00490516 | ACP-104 in Acutely Psychotic Subjects With Schizophrenia | COMPLETED | PHASE2 | 2007-06 | 2008-02 | 2008-02 |
| NCT00477672 | A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | COMPLETED | PHASE3 | 2007-06 | 2009-07 | 2009-06 |
| NCT00361166 | Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone | COMPLETED | PHASE2 | 2005-08 | 2007-03 | |
| NCT01518309 | An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients | COMPLETED | PHASE2 | 2004-11-17 | 2013-05-02 | 2013-05-02 |
| NCT00087542 | Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug | COMPLETED | PHASE2 | 2004-03 | 2005-12 | |